Business Context and Reporting Period
Company: Silexion Therapeutics Corp (SLXN)
Filing Type: Form 8-K (Current Report)
Report Date: August 21, 2026 (Earliest event reported: August 18, 2026)
Context: The Company, a Cayman Islands exempted company, reported receiving a delisting notice from the Nasdaq Listing Qualifications Department regarding non-compliance with continued listing standards.
Key Financial Metrics
Shareholders' Equity: $44,000 (as reported in the Form 10-Q for the period ended June 30, 2026).
Required Minimum Equity: $2,500,000 (per Nasdaq Listing Rule 5550(b)(1)).
Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for revenue, profit, cash flow, or debt levels for the current period.
Material Changes and Listing Deficiency
- Delisting Notice: Received on August 18, 2026, due to failure to maintain the minimum $2.5 million shareholders' equity requirement.
- Compliance Status: The Company previously believed it had restored compliance on a pro forma basis as of June 30, 2026, but subsequent net losses resulted in current non-compliance.
- Monitoring Period: The Company is subject to a Mandatory Hearings Panel Monitor following a decision dated September 23, 2025. Under this monitor, Nasdaq cannot grant additional time to regain compliance for deficiencies arising during the one-year period.
Outlook, Management Commentary, and Risks
Management Action: The Company intends to request an appeal before a Nasdaq Hearings Panel by August 25, 2026. The appeal strategy involves presenting evidence of steps taken and planned to restore shareholders' equity.
Outlook: There is no assurance that the appeal will be successful or that additional time will be granted.
Consequences of Failure: If the appeal is unsuccessful, trading in the Company's ordinary shares and warrants will be suspended, and a Form 25-NSE will be filed to remove the securities from Nasdaq listing.
Risks: The filing highlights risks related to the potential loss of listing status and the uncertainty of restoring the required equity level.
Investor Verification Checklist
- Verify the exact date and status of the appeal request to the Nasdaq Hearings Panel (deadline: August 25, 2026).
- Review the Form 10-Q for the quarter ended June 30, 2026, to understand the specific net losses that eroded shareholders' equity to $44,000.
- Confirm the Company's specific capital raise or operational plans intended to restore equity to the $2.5 million threshold.
- Monitor for any Form 25-NSE filings which would indicate the final removal of securities from Nasdaq.